The Management of Thrombotic Thrombocytopenic Purpura in 2005

ABSTRACT

Thrombotic thrombocytopenic purpura is an uncommon disease that often presents with a striking and acute clinical picture. Although first described more than 80 years ago, the therapy has changed little since the discovery that plasma, and then plasma exchange, could bring about a remarkable response, changing survival rates from 20% to more than 80%. However, although plasma exchange is now considered the standard of care, there is still considerable discussion concerning the appropriate schedules for therapy and the types of fluids that should be used. Because plasma exchange (PE) is not effective in all patients, and at least 30% of patients will have one or more relapses, several adjuvant therapies have also been used. Most recently, this has included the use of rituximab to achieve an immunomodulatory effect.

Thrombotic thrombocytopenic purpura (TTP) - plasma exchange - cryosupernatant - rituximab

REFERENCES

• 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc NY Pathol Soc. 1924;  24 21-24
• 2 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries.  Arch Intern Med. 1925;  36 89-93
• 3 Rubinstein M A, Kagan B M, MacGillviray M H, Merliss R, Sacks H. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions.  Ann Intern Med. 1959;  51 1409-1419
• 4 Bukowski R M, King J W, Hewlett J S. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.  Blood. 1977;  50 413-417
• 5 Amorosi E I, Ultmann J E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.  Medicine (Baltimore). 1966;  45 139-159
• 6 Rock G, Shumak K H, Buskard N A and the Members of the CASG et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.  N Engl J Med. 1991;  325 393-397
• 7 Bell W R, Braine H G, Ness P M, Kickler T S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.  N Engl J Med. 1991;  325 398-403
• 8 Byrnes J J, Khurana M. Treatment of thrombotic thrombocytopenic purpuras with plasma.  N Engl J Med. 1977;  297 1386-1389
• 9 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 10 Rock G, Shumak K H, Sutton D M et al.. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpuras. Members of the Canadian Apheresis Group.  Br J Haematol. 1996;  94 383-386
• 11 Rock G, Anderson D, Clark W et al.. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet?.  Br J Haematol. 2005;  129 79-86
• 12 Zeigler Z R, Shadduck R K, Gryn J F et al.. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP).  J Clin Apheresis. 2001;  16 19-22
• 13 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 14 Furlan M, Robles R, Galbusera M et al.. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
• 15 Rock G, Yousef H, Neurath D, Lu M. Levels of ADAMTS-13 in fresh, stored and solvent detergent treated plasma. Paper presented at: the CSTM Meeting 2005 Banff, Canada;
• 16 Yarranton H, Lawrie A S, Purdy G, Mackie I J, Machin S J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.  Transfus Med. 2003;  14 39-44
• 17 Moake J L, Chintagumpala M, Turner N et al.. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of TTP.  Blood. 1994;  84 490-497
• 18 Tandon N N, Rock G, Jamieson G A. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura.  Br J Haematol. 1994;  88 816-825
• 19 Morrison J, McMillan R. Elevated platelet-associated lgG in thrombotic thrombocytopenic purpura.  JAMA. 1977;  238 1944-1945
• 20 Leung D Y, Moake J L, Havens P L, Kim M, Pober J S. Lytic anti-endothelial cell antibodies in haemolytic-uraemic syndrome.  Lancet. 1988;  2 183-186
• 21 Gilcher R O, Strauss R G, Clavarella D et al.. Management of renal disorders.  J Clin Apheresis. 1993;  8 258-269
• 22 AABB Extracorporeal Therapy Committee .Guidelines for Therapeutic Hemapheresis: 1992-3. Bethesda, MD; American Association of Blood Banks 1992
• 23 Bandarenko N, Brecher M E. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange.  J Clin Apheresis. 1998;  13 133-141
• 24 Stegmayr B G. Plasmapheresis in severe sepsis or septic shock.  Blood Purif. 1996;  14 94-101
• 25 Stegmayr B G, Banga R, Berggren L, Norda R, Rydvall A, Vikerfors T. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure.  Crit Care Med. 2003;  31 1730-1736
• 26 Valbonesi M, Giannini G, Carlier P et al.. TTP treated with the automatic cascade filtration module (DIDECO AutoCFM). WAA September 2002 (abst)
• 27 Gaddis T G, Guthrie T HJ, Drew M J, Sahud M, Howe R B, Mittelman A. Treatment of plasma refractory thrombotic thrombocytopenic purpuras with protein A immunoabsorption.  Am J Hematol. 1997;  55 55-58
• 28 Snyder H W, Mittelman A, Oral A et al.. Treatment of cancer chemotherapy associated thrombotic thrombocytopenia purpura/hemolytic uremic syndrome by protein A immunoabsorption of plasma.  Cancer. 1993;  71 1882-1892
• 29 Bukowski R M, Hewlett J S, Reimer R R, Groppe C W, Weick J K, Livingston R B. Therapy of thrombotic thrombocytopenic purpura: an overview.  Semin Thromb Hemost. 1981;  7 1-14
• 30 Amir J, Krauss S. Treatment of thrombotic thrombocytopenic purpura with antiplatelet drugs.  Blood. 1973;  42 27-33
• 31 Amorosi E L, Karpatkin S. Antiplatelet treatment of thrombotic thrombocytopenic purpura.  Ann Intern Med. 1977;  86 102-106
• 32 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS-13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4043-4049
• 33 Cataland S R, George I N, Kraut E H et al.. Improved clinical outcome and ADAMTS-13 activity following cyclosporine therapy in patients with TTP.  Blood. 2004;  104 243 , (abst)
• 34 Zheng X L, Pallera A M, Goodnough I T et al.. Remission of chronic thrombotic thrombocytopenic purpura treated with cyclophosphamide and rituximab.  Ann Intern Med. 2003;  138 105-108
• 35 Rock G, Kelton J G, Shumak K H, Buskard N A, Sutton D MC. and Members of the CAG . Laboratory abnormalities in thrombotic thrombocytopenic purpura.  Br J Haematol. 1998;  103 1031-1036
• 36 Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.  Ann Oncol. 2003;  14 520-526
• 37 Maloney D G, Grillo-Lopez A J, Bodkin D J et al.. IDEC-C2B8: results of phase I multiple dose trail in patients with relapsed non-Hodgkin's lymphoma.  J Clin Oncol. 1997;  10 3266-3274
• 38 Davis T A, White C A, Grillo-Lopez A J et al.. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of phase II trail of rituximab.  J Clin Oncol. 1999;  6 1851-1857
• 39 Ciiffier B, Lapage E, Briere J et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.  N Engl J Med. 2002;  346 235-242
• 40 Hainsworth J D, Litchy S, Barton J H et al.. Single agent rituximab as first line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.  J Clin Oncol. 2003;  21 1746-1751
• 41 van der Kolk L, Baars J, Prins M, van Oers M. Rituximab treatment results in impaired secondary humoral immune responses.  Blood. 2002;  100 2257-2259
• 42 Koulova L, Alexandrescu D, Dutcher J P, O'Boyle K P, Eapen S, Wiernik P H. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.  Am J Hematol. 2005;  78 49-54
• 43 Chemnitz J, Draube A, Scheid C et al.. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.  Am J Hematol. 2002;  71 105-108
• 44 Shumak K H, Rock G A, Nair R C. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group.  Ann Intern Med. 1995;  122 569-572
• 45 Schneppenheim R, Budde U, Oyen F et al.. Von Willebrand factor cleaving protease and ADAMTS-13 mutations in childhood TTP.  Blood. 2003;  101 1845-1850
• 46 Mannucci M, Canciani M T, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of ADAMTS-13 that cleaves von Willebrand factor.  Blood. 2001;  98 2730-2735
• 47 Moore J C, Haward C PM, Warentin T E, Kelton J G. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.  Blood. 2001;  98 1842-1846
• 48 Studt J D, Kremer Hovinga J A, Rodonic R et al.. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS-13 inhibitory autoantibodies in identical twins.  Blood. 2004;  103 4195-4197
• 49 Veyradier A, Obert B, Houllier A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.  Blood. 2001;  98 1765-1772
• 50 Motto D, Zhang W, Zhu G et al.. Additional environmental and/or genetic factors are required to trigger TTP in ADAMTS-13-deficient mice.  Blood. 2004;  104 77 , (abst)
• 51 Gerritsen H E, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease.  Blood. 2001;  98 1654-1661
• 52 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.  Blood. 2001;  98 1662-1666
• 53 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic ursemic syndrome: the role of von Willebrand factor-cleaving protease.  Best Pract Res Clin Haematol. 2001;  14 437-454
• 54 Studt J D, Kremer Hovinga J A, Alberio L, Bianchi V, Lämmle B. von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.  Swiss Med Wkly. 2003;  133 325-332
• 55 Barbot J, Costa E, Guerra M et al.. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease.  Br J Haematol. 2001;  113 649-651
• 56 Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS-13).  Ann Hematol. 2002;  81 430-435
• 57 Mori Y, Wada H, Gabazza E C et al.. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.  Transfusion. 2002;  42 572-580
• 58 Vesely S K, George J N, Lämmle B et al.. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
• 59 Rock G, Shumak K, Kelton J, Blanchette V, Buskard N, Spasoff R. and the Members of the CASG . Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange.  Transfusion. 1992;  32 710-714
• 60 George J N. ADAMTS-13 Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Curr Hematol Rep. 2005;  4 167-169